Indeed, D-PROTAC has been found within in vitro studies capable of reducing both FAK and the phosphorylated form (pFAK) in NSCLC cells, especially those with KRAS mutation, while defectinib was shown to reduce only pFAK. Here, KRAS is linked to non-small cell lung carcinoma.